
Media


Cocrystal Pharma Partners With hVIVO in New Antiviral Flu Treatment Phase 2 Trial
IDSE Infectious Disease Special Edition
Cocrystal Antiviral Flu Candidate Shows Potential for Once-Daily Treatment in Phase 1 Trial
IDSE Infectious Disease Special Edition
Life Science Leader
CoCrystal's Co-Ceos

Cocrystal, NIAID expand partnership for Covid-19 protease inhibitors Pharmaceutical Technology

Empowered Patient Podcast with Karen Jagoda
Drug Development Platform Creating Novel Antiviral Therapeutics for Pandemics and Seasonal Influenza with Sam Lee and Jim Martin Cocrystal Pharma
Cocrystal Pharma advancing programs in high-value antiviral drug targets
BioTuesday.com
Cocrystal’s Proprietary Technologies in Antiviral Therapeutics to Combat COVID-19

C-Suite Interview with Cocrystal Pharma (COCP) Interim Co-CEOs Sam Lee, President & James Martin, CFO

Nasdaq Facebook Live Interview

Nasdaq Bell Ringing Ceremony

Cocrystal Overview
